Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Cash & Current Investments (2020 - 2026)

Nautilus Biotechnology has reported Cash & Current Investments over the past 7 years, most recently at $95.9 million for Q1 2026.

  • Quarterly results put Cash & Current Investments at $95.9 million for Q1 2026, down 30.94% from a year ago — trailing twelve months through Mar 2026 was $95.9 million (down 30.94% YoY), and the annual figure for FY2025 was $103.4 million, down 20.39%.
  • Cash & Current Investments reached $95.9 million in Q1 2026 per NAUT's latest filing, down from $103.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $324.1 million in Q1 2022 and bottomed at $95.9 million in Q1 2026.
  • Median Cash & Current Investments over the past 5 years was $167.3 million (2023), compared with a mean of $175.9 million.
  • The largest annual shift saw Cash & Current Investments soared 47423.79% in 2022 before it crashed 48.37% in 2023.
  • Over 5 years, Cash & Current Investments stood at $184.5 million in 2022, then fell by 5.99% to $173.4 million in 2023, then decreased by 25.1% to $129.9 million in 2024, then decreased by 20.39% to $103.4 million in 2025, then dropped by 7.29% to $95.9 million in 2026.
  • Business Quant data shows Cash & Current Investments for NAUT at $95.9 million in Q1 2026, $103.4 million in Q4 2025, and $131.4 million in Q3 2025.